About US
Contact us
-
Top Medicare prescribers get top payments from drugmakers: Modern HealthcarePharma companies that make payments to doctors--and the doctors who receive those payments--have repeatedly insisted there's no link between those payments and prescriptions. But data onMedicare's top2015/5/28
-
As Bayer preps for its slim-down, a restructuring looms--but jobs are safe, CEO saysAsBayermoves closer to hiving off its plastics businesses and becoming a life sciences-focused company, a restructuring is afoot, the company said Wednesday. But it's one that won't cost the drugmaker2015/5/28
-
GSK, Pfizer among Big Pharmas bailing on Chinese sales as provinces squeeze pricesWhenChinasaid it would lift price caps on drugs, the move was heralded as welcome relief for drugmakers. But asBloombergreports, the optimism may have been premature. Yes, the price caps won't affect2015/5/27
-
Valeant, Actavis on verge of FDA nods in IBS for Xifaxan, eluxadolineGet ready for a showdown in the irritable bowel syndrome market. Valeant Pharmaceuticals ($VRX) is set to hear from the FDA this week on a new, broader use in IBS-D for Xifaxan, a drug it bought along2015/5/27
-
Celgene's next-gen psoriasis drug dissed by German cost watchdogCelgene's ($CELG)Otezlahas been rolling along in the U.S. toward its aspirations as a blockbuster, picking up an approval for psoriatic arthritis before grabbing an FDA nod for the much wider use for2015/5/26
-
Merck's Keytruda, BMS' Opdivo score European nods to keep immuno-oncology race blazingMerck's ($MRK)Keytruda--which has been leapfrogged by Bristol-Myers Squibb ($BMY) rivalOpdivosince becoming the first PD-1 blocker to roll out in the U.S.--gained some regulatory ground in Europe on F2015/5/26
-
Valeant chief Pearson won't be scared off by M&A 'bubble'Valeant ($VRX) CEO J. Michael Pearson is plenty familiar with the pharma M&A space; after all, he's made scores of deals since taking up the post in 2008. And the way he sees it, with pickups happ2015/5/25
-
Pfizer could buy GSK, but would Shire or Perrigo offer better targets?The speculation is building this week that Pfizer ($PFE) will either attempt another megadeal with GlaxoSmithKline ($GSK) or another run on AstraZeneca ($AZN). Either would cut Pfizer's tax rate and g2015/5/25
-
CVS Health gets more drug pricing clout with $12B deal for OmnicareGet ready for more of a squeeze on drugs used by seniors. CVS Health ($CVS) agreed to pay $12.7 billion for the pharmacy services company Omnicare ($OCR), which specializes in assisted living and long2015/5/22
-
Endo sews up $9.2B financing for Par Pharma buyoutEarlier this week, Endo ($ENDP) inked a pact to nabPar Pharmaceuticalfor $8 billion. But to do that, it'll need a loan, and it's agreed to a $9.275 billion loan package to back the acquisition. Deutsc2015/5/22